


PHARMACEUTICAL 2019



MyoKardia Inc. Rank 64 of 371





PHARMACEUTICAL 2019



MyoKardia Inc. Rank 64 of 371

The relative strengths and weaknesses of MyoKardia Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MyoKardia Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 88% points. The greatest weakness of MyoKardia Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 60%, being 391% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	319,446
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	36,677
Liabilities, Non-Current	9.0
Other Assets	82,669
Other Compr. Net Income	125
Other Expenses	0
Other Liabilities	0
Other Net Income	5,953
Property and Equipment	5,138
Research and Development	68,774
Revenues	33,558
Selling, General and Administrative Expense	38,435

Output Variable	Value in 1000 USD
Assets	407,253
Liabilities	36,686
Expenses	107,209
Stockholders Equity	370,567
Net Income	-67,698
Comprehensive Net Income	-67,636
Economic Capital Ratio	60%